October Pharma results, Q3 2023
Net profit, assets, equity and cash flow for Q3 2023, against the same period a year earlier, from the published financial statements.
Net profit49.02 millionEGP · −55.0% vs the same period a year earlier
Total assets1.1 billionEGP · +29.2% vs the same period a year earlier
Shareholders' equity538 millionEGP · +33.3% vs the same period a year earlier
Operating cash flow19.43 millionEGP · +125.2% vs the same period a year earlier
In short
- October Pharma's net profit for Q3 2023 was about 49.02 million EGP, down −55.0% from 109 million EGP in Q3 2022.
- Total assets at the end of Q3 2023 were about 1.1 billion EGP, and shareholders' equity about 538 million EGP.
- Operating cash flow for Q3 2023 was positive at 19.43 million EGP.
Key lines against the same period a year earlier
This periodQ3 2022Change
Net profit49.02 million109 million−55.0%
Gross profit137 million274 million−50.0%
Total assets1.1 billion849 million+29.2%
Total liabilities559 million445 million+25.5%
Shareholders' equity538 million404 million+33.3%
Total liabilities and equity1.1 billion849 million+29.2%
Operating cash flow19.43 million-77.15 million+125.2%
Investing cash flow-3.33 million-73.29 million+95.5%
Financing cash flow-18.75 million146 million−112.8%
Net change in cash-2.65 million-4.03 million+34.2%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy